What dose constraints do you use for RCC/Kidney SBRT?

As is often the case, there is no single answer to this question, and the ALARA principle should always be kept in mind. A good starting place to determine your OAR constraints for a given case is to consider the clinical context. Ultimately, in deciding on allowable OAR constraints, one has to cons...

I think FASTRACK II is our best evidence in this space, and I have switched to 3-fraction SABR (I rarely see tumors that meet criteria for single fraction, which is simply a reflection of local referral patterns). We are using a similar strategy in the NRG-GU012 (SAMURAI trial). For patients not eli...

In essence, FASTRACK emphasizes conformality and minimizing dose splash of the intermediate IDLs to the kidney parenchyma. The Glicksman/Toronto approach does a similar thing, maximizing the uninvolved renal cortex (URC), which essentially is the volume of kidney cortex outside of the 17.5 Gy (50% I...